Interactions on record — worth a quick check against your medications. Based on 5 of 9 ingredients. Check your meds →
Dietary supplement

Vegetarian Women's Probiotic 50 Billion CFU Ingredients & Drug Interactions

by revly

Capsule Category: Other Combinations
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Vegetarian Women's Probiotic 50 Billion CFU is a dietary supplement by revly with 9 active ingredients. Its ingredients are commonly taken for digestive and gut health, prebiotic to support good bacteria, constipation relief.Based on those ingredients, 302 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Bifidobacterium breve BB-3, Lactobacillus acidophilus LA-14, Lactiplantibacillus plantarum Lp-115. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Vegetarian Women's Probiotic 50 Billion CFU by revly

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 9 active ingredients.
  • “Prebiotic Blend” is a proprietary blend — the label gives one combined amount (50 mg) without saying how much of each component you get.
  • “Proprietary Bifidobacterium Blend” is a proprietary blend — the label doesn't break down how much of each component you get.
  • “Proprietary Lactobacillus/Lactococcus Blend” is a proprietary blend — the label doesn't break down how much of each component you get.

This is a 9-ingredient probiotic blend designed for women's gut health. The active ingredients are beneficial live bacteria — five individual strains plus three proprietary blends — along with two prebiotics (Fructooligosaccharides and Larch Arabinogalactan) that feed the good bacteria.

The live bacteria strains we could check are Lactobacillus acidophilus, Bifidobacterium breve, and Lactiplantibacillus plantarum. The formula also includes inactive ingredients like cellulose and magnesium stearate for the capsule and tablet structure.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: Supports urinary tract and vaginal health.
  • We looked for evidence on: Bacterial vaginosis, Urinary tract infection, Vaginal yeast infection, Urinary health.
  • The strongest evidence on file: Lactobacillus Acidophilus is rated "Possibly Effective" for Bacterial vaginosis (Natural Medicines).
  • Also on file: Lactobacillus Acidophilus is rated "Insufficient Reliable Evidence To Rate" for Urinary tract infections (UTIs).
  • Also on file: Lactiplantibacillus Plantarum is rated "Insufficient Reliable Evidence To Rate" for Bacterial vaginosis, Urinary tract infections (UTIs).

The evidence picture is mixed. Lactiplantibacillus plantarum shows possibly effective ratings for eczema, high cholesterol, ulcerative colitis, and the common cold.

Lactobacillus acidophilus is possibly effective for irritable bowel syndrome, H. pylori infection, antibiotic-associated diarrhea, and bacterial vaginosis. For the other ingredients and conditions — like Fructooligosaccharides for constipation, diabetes, or cholesterol — the evidence isn't established in the data we hold, or they're rated possibly ineffective.

If you're considering this for a specific condition, your pharmacist or doctor can help you understand what the science actually supports.

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 5 of the 5 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 5 of 5.
  • General safety write-ups exist for 5 of 5.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

The live bacteria in this product are generally well tolerated in healthy adults. Gastrointestinal side effects like bloating, flatulence, abdominal pain, and diarrhea can occur but are uncommon.

Fructooligosaccharides and Larch Arabinogalactan may cause gas and bloating, especially at higher doses — though studies show FOS at everyday amounts doesn't consistently increase these symptoms. If you're very ill, immunocompromised, or in intensive care, talk with your doctor before starting any probiotic.

Safety data for some ingredients are limited, so it's worth checking in with your healthcare provider, especially if you're on other medications or have a serious condition.

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 4 of the 5 matched ingredients can interact with medications — Lactobacillus Acidophilus, Larch Arabinogalactan, Bifidobacterium Breve, Lactiplantibacillus Plantarum.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: immunosuppressants / transplant drugs.
  • For scale: 302 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

If you take antibiotic drugs, check with your pharmacist — you'll need to separate doses from this product by at least 2 hours so the antibiotics don't kill the live bacteria. If you take immunosuppressants (drugs to weaken your immune system, often used after transplant), talk to your doctor or pharmacist before starting, since larch arabinogalactan may interfere with how they work.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

This probiotic is a reasonable choice for healthy adults looking to support their gut. If you take antibiotics or immune-suppressing drugs, you'll need to time your doses carefully and talk to your pharmacist first.

People who are very ill or immunocompromised should check with their doctor before starting.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 5 of 9 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Nov 22, 2024.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Vegetarian Women's Probiotic 50 Billion CFU, straight from the product label.

Brand revly
Net contents 30 Capsule(s)
Market status On market
Date entered into DSLD Nov 22, 2024
DSLD ID 319251
Product type Other Combinations
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegetarian, Adult Female (18 - 50 Years)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Vegetarian Women's Probiotic 50 Billion CFU by revly, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Vegetarian Capsule(s)
Maximum serving Sizes:
1 Vegetarian Capsule(s)
Servings per container
30
IngredientAmount% DV
Bifidobacterium animalis lactis BL-040 NP--
Lactococcus lactis LL-230 NP--
Lactobacillus casei LC-110 NP--
Lactobacillus salivarius LS-330 NP--
Fructooligosaccharides0 NP--
Lactobacillus acidophilus LA-140 NP--
Prebiotic Blend50 mg--
Larch Arabinogalactan0 NP--
Bifidobacterium breve BB-30 NP--
Lactiplantibacillus plantarum Lp-1150 NP--
Proprietary Bifidobacterium Blend0 NP--
Proprietary Lactobacillus/Lactococcus Blend0 NP--

Other ingredients: Modified Cellulose, Water, Cellulose, Magnesium Stearate, Silica, Calcium Silicate

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formula

Woman's probiotic 50 billion CFU (Colony Forming Units at end of shelf life.) per serving

Women's health

Formulation

Supports urinary tract and vaginal health

FDA Statement of Identity

Dietary Supplement

Precautions

Keep out of reach of children. For adults use only.

Caution: Do not exceed recommended dosage. Do not use if seal is broken or missing.

Consult a physician if you are pregnant, nursing, or taking any prescription medications.

Storage

Store in a cool, dry place. Away from direct sunlight.

FDA Disclaimer Statement

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Suggested/Recommended/Usage/Directions

Suggested use: Adults take 1 capsule with food daily, or as directed by a healthcare professional.

See for yourself

Vegetarian Women's Probiotic 50 Billion CFU by revly label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Vegetarian Women's Probiotic 50 Billion CFU by revly

These are the 9 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Vegetarian Capsule(s) Dosage formCapsule Servings per container30 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Prebiotic Blend

50 mg per serving

Proprietary Bifidobacterium Blend

0 NP per serving

Proprietary Lactobacillus/Lactococcus Blend

0 NP per serving

Other (inactive) ingredients: Modified Cellulose, Water, Cellulose, Magnesium Stearate, Silica, Calcium Silicate. These complete the product’s ingredient list but are not active constituents.

Interaction report

Vegetarian Women's Probiotic 50 Billion CFU by revly Drug Interactions

Want to check YOUR meds against Vegetarian Women's Probiotic 50 Billion CFU?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
302Drugs
302 Moderate

Each ingredient & the kinds of drugs it affects

For each ingredient in Vegetarian Women's Probiotic 50 Billion CFU with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Bifidobacterium breve BB-31 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium breve with antibiotic drugs might decrease the effectiveness of B. breve.
Since B. breve preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. breve preparations by at least 2 hours.

Likelihood Probable Evidence D

Lactobacillus acidophilus LA-141 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lactobacillus acidophilus with antibiotic drugs might decrease the effectiveness of L. acidophilus.
L. acidophilus preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. acidophilus preparations by at least two hours.

Likelihood Probable Evidence D

Lactiplantibacillus plantarum Lp-1151 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lactiplantibacillus plantarum with antibiotic drugs might decrease the effectiveness of L. plantarum.
L. plantarum preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. plantarum preparations by at least two hours.

Likelihood Probable Evidence D

Larch Arabinogalactan1 drug type · 121 drugs

Immunosuppressants

Theoretically, larch arabinogalactan might interfere with immunosuppression therapy due to immunostimulant effects. Immunosuppressant drugs include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and other drugs.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Vegetarian Women's Probiotic 50 Billion CFU, from the product label.

revly

See all revly products
Name
Amazon.Com Services LLC
Street Address
410 Terry Avenue N.
City
Seattle
State
WA
ZipCode
98109
Pharmacist Counseling Corner

Vegetarian Women's Probiotic 50 Billion CFU by revly: Common Questions

Does Vegetarian Women's Probiotic 50 Billion CFU by revly interact with any medications?
Yes. Based on its ingredients, Vegetarian Women's Probiotic 50 Billion CFU has a known interaction with 302 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Vegetarian Women's Probiotic 50 Billion CFU contains 9 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take this probiotic while I'm on antibiotics?
Yes, but timing matters. Antibiotics can kill the live bacteria in this supplement, which defeats the purpose. Separate your antibiotic dose and your probiotic dose by at least 2 hours — your pharmacist can help you schedule them. Once your antibiotics are done, you can resume your normal routine with the probiotic.
Will this help my irritable bowel syndrome or bacterial vaginosis?
Lactobacillus acidophilus is rated possibly effective for both IBS and bacterial vaginosis. That means the evidence suggests it may help, but it's not a sure thing. Talk with your doctor about whether this probiotic makes sense for your specific situation.
What side effects should I expect?
Bloating, flatulence, and mild abdominal discomfort are the most common, especially when you first start. These tend to be uncommon and usually mild. If you have severe or ongoing digestive issues, let your pharmacist know.
Is there enough safety data on this product?
The live bacteria are generally well tolerated in healthy people. Some ingredients have limited safety data, so it's worth talking to your doctor if you have a serious medical condition, a weak immune system, or are very ill before you start.
What are the prebiotics in this formula for?
Fructooligosaccharides and Larch Arabinogalactan are prebiotics — they feed the good bacteria in your gut so they can thrive. However, the evidence for their benefits on constipation, cholesterol, or blood sugar isn't established in the data we hold.
Does this contain any fillers or inactive ingredients?
Yes, the capsule contains modified cellulose, cellulose, magnesium stearate, silica, and calcium silicate. These are standard inactive ingredients that help form and preserve the supplement.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Vegetarian Women's Probiotic 50 Billion CFU is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Vegetarian Women's Probiotic 50 Billion CFU label
Go deeper

The Full Monographs Behind Vegetarian Women's Probiotic 50 Billion CFU’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Fructo-oligosaccharides (fos)

Fructo-oligosaccharides (FOS) are a type of soluble fiber that acts as a prebiotic, meaning they feed the helpful bacteria in your gut. They are generally considered safe for most people in...

Read the full Fructo-oligosaccharides (fos) monograph →
Herb & supplement monograph

Larch Arabinogalactan

Interacts with 121 drugs

Larch arabinogalactan is a soluble fiber from larch trees that is mainly used as a prebiotic and for immune support. Early research is interesting but limited, and most claims are not yet fi...

Read the full Larch Arabinogalactan monograph →
Herb & supplement monograph

Bifidobacterium Breve

Interacts with 182 drugs

Bifidobacterium breve is a 'friendly' gut bacterium taken as a probiotic, most often to support digestion and balance the gut microbiome. Some studies suggest possible benefits for certain d...

Read the full Bifidobacterium Breve monograph →
Herb & supplement monograph

Lactobacillus Acidophilus

Interacts with 182 drugs

Lactobacillus acidophilus is a 'friendly' bacterium used as a probiotic to support gut and vaginal health. It is generally well tolerated in healthy people, and there is reasonable evidence...

Read the full Lactobacillus Acidophilus monograph →
Herb & supplement monograph

Lactiplantibacillus Plantarum

Interacts with 182 drugs

Lactiplantibacillus plantarum is a 'friendly' bacterium (probiotic) found in fermented foods and many supplements, studied mainly for digestive health. It is generally well tolerated in heal...

Read the full Lactiplantibacillus Plantarum monograph →
Sources

Sources & How We Checked

Vegetarian Women's Probiotic 50 Billion CFU's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 50 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Fructo-oligosaccharides (fos) 6 references
  1. Briet F, et al. Symptomatic response to varying levels of fructo-oligosaccharides consumed occasionally or regularly. Eur J Clin Nutr 1995;49:501-7.
  2. Bouhnik Y, Vahedi K, Achour L, et al. Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. J Nutr 1999;129:113-6. PubMed
  3. Cummings JH, Macfarlane GT, Englyst HN. Prebiotic digestion and fermentation. Am J Clin Nutr 2001;73:415S-420S. PubMed
  4. Souza DDS, Tahan S, Weber TK, Araujo-Filho HB, de Morais MB. Randomized, double-blind, placebo-controlled parallel clinical trial assessing the effect of fructooligosaccharides in infants with constipation. Nutrients. 2018;10(11). pii: E1602. PubMed
  5. Andermann TM, Fouladi F, Tamburini FB, et al. A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. Transplant Cell Ther 2021;27(11):932. PubMed
  6. Dou Y, Yu X, Luo Y, Chen B, Ma D, Zhu J. Effect of Fructooligosaccharides Supplementation on the Gut Microbiota in Human: A Systematic Review and Meta-Analysis. Nutrients 2022;14(16):3298. PubMed

See these in context on the Fructo-oligosaccharides (fos) monograph →

Lactobacillus Acidophilus 15 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013;48(10):1127-35 PubMed
  3. Chatterjee S, Kar P, Das T, Ray S, Gangulyt S, Rajendiran C, Mitra M. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated
  4. Shavakhi A, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M,Minakari M, Shavakhi S, Gholamrezaei A. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-c
  5. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  6. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  7. Kumar S, Kumar R, Rohilla L, Jacob N, Yadav J, Sachdeva N. A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: A randomized, double-blind, and placebo-controlled pilot study. Pediatr Diabete
  8. Shahriari A, Karimi E, Shahriari M, Aslani N, Khooshideh M, Arab A. The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial PubMed
  9. Xiao SD, Zhang DZ, Lu H, et al. Multicenter, randomized, controlled trial of heat-killed Lactobacillus acidophilus LB in patients with chronic diarrhea. Adv Ther. 2003;20(5):253-60.
  10. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  11. Ozer M, Goksu SY, Shahverdiani A, Mustafa M. Lactobacillus acidophilus-induced endocarditis and associated splenic abscess. Case Rep Infect Dis 2020;2020:1382709.
  12. Sadrin S, Sennoune S, Gout B, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liver Dis 2020;52(5):534-540. PubMed
  13. Stoffer JN, Slingsby TJ, Giuliari GP. Lactobacillus acidophilus endophthalmitis after intravitreal bevacizumab injection requiring intraocular lens explantation. Can J Ophthalmol 2022;57(1):e21-e22. PubMed
  14. Cukovic-Cavka S, Likic R, Francetic I, Rustemovic N, Opacic M, Vucelic B. Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease. Digestion 2006;73(2-3):107-10.
  15. Hui J, Ren Y, Wang Y, Han Q. Lactobacillus acidophilus endophthalmitis postcataract operation: A case report with a literature review. Ocul Immunol Inflamm 2023.

See these in context on the Lactobacillus Acidophilus monograph →

Larch Arabinogalactan 8 references
  1. D'Adamo P. Larch arabinogalactan. J Naturopath Med 1996;6:33-7.
  2. Kelly GS. Larch arabinogalactan: Clinical relevance of a novel immune-enhancing polysaccharide. Alt Med Rev 1999;4:96-103.
  3. Marett R, Slavin JL. No long-term benefits of supplementation with arabinogalactan on serum lipids and glucose. J Am Diet Assoc 2004;104:636-9.
  4. Robinson RR, Feirtag J, Slavin JL. Effects of dietary arabinogalactan on gastrointestinal and blood parameters in healthy human subjects. J Am Coll Nutr 2001;20:279-85. PubMed
  5. Udani JK, Singh BB, Barrett ML, Singh VJ. Proprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: a randomized, double-blind, placebo-controlled, pilot study in healthy volunteers. Nutr J 2010;9:32. PubMed
  6. Grube B, Stier H, Riede L, Gruenwald J. Tolerability of a proprietary larch arabinogalactan extract: a randomized, double-blind, placebo-controlled clinical trial in healthy subjects. Food Nutr Sci 2012;3:1533-8. DOI
  7. Dion C, Chappuis E, Ripoll C. Does larch arabinogalactan enhance immune function? A review of mechanistic and clinical trials. Nutr Metab (Lond) 2016;13:28. PubMed
  8. Riede L, Grube B, Gruenwald J. Larch arabinogalactan effects on reducing incidence of upper respiratory tract infections. Curr Med Res Opin 2013;29(3):251-8.

See these in context on the Larch Arabinogalactan monograph →

Bifidobacterium Breve 9 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  4. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr. 2010;156(4):679-81. PubMed
  5. Sakurai Y, Watanabe T, Miura Y, et al. Clinical and bacteriologic characteristics of six cases of Bifidobacterium breve bacteremia due to probiotic administration in the neonatal intensive care unit. Pediatr Infect Dis J 2022;41(1):62-65. PubMed
  6. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  7. Wakabayashi Y, Nakayama S, Yamamoto A, et al. First case of necrotizing fasciitis and bacteremia caused by Bifidobacteriumbreve. Anaerobe 2022;76:102613.
  8. Takeda Y, Ota K, Kondo A, et al. A case of necrotizing fasciitis caused by Bifidobacterium breve. IDCases 2022;31:e01667. PubMed
  9. Suwantarat N, Romagnoli M, Wakefield T, Carroll KC. Ventriculoperitoneal shunt infection caused by Bifidobacterium breve. Anaerobe 2014;28:1-3. PubMed

See these in context on the Bifidobacterium Breve monograph →

Lactiplantibacillus Plantarum 12 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012;18(30):4012-8.
  3. Krag A, Munkholm P, Israelsen H, von Ryberg B, Andersen KK, Bendtsen F. Profermin is efficacious in patients with active ulcerative colitis--a randomized controlled trial. Inflamm Bowel Dis. 2013;19(12):2584-92. PubMed
  4. Topcuoglu S, Gursoy T, Ovali F, Serce O, Karatekin G. A new risk factor for neonatal vancomycin-resistant Enterococcus colonisation: bacterial probiotics. J Matern Fetal Neonatal Med. 2015;28(12):1491-4. PubMed
  5. Kumar S, Kumar R, Rohilla L, Jacob N, Yadav J, Sachdeva N. A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: A randomized, double-blind, and placebo-controlled pilot study. Pediatr Diabete
  6. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  7. Axling U, Önning G, Martinsson Niskanen T, Larsson N, Hansson SR, Hulthén L. The effect of Lactiplantibacillus plantarum 299v together with a low dose of iron on iron status in healthy pregnant women: A randomized clinical trial. Acta Obstet Gynecol Scand
  8. Matsuura H, Kiura Y, Ito T, et al. Lactobacillus bacteremia: a diagnostic clue of rectal cancer. QJM. 2021;114(2):122-123. PubMed
  9. Lazou Ahrén I, Berggren A, Teixeira C, Martinsson Niskanen T, Larsson N. Evaluation of the efficacy of Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2 on aspects of common cold infections in children attending day care: a randomised, doub
  10. Busch R, Gruenwald J, Dudek S. Randomized, double blind and placebo controlled study using a combination of two probiotic lactobacilli to alleviate symptoms and frequency of common cold. Food Nutr Sci 2013;4(11A):13-2. DOI
  11. Bengtsson J, Adlerberth I, Östblom A, Saksena P, Öresland T, Börjesson L. Effect of probiotics (Lactobacillus plantarum 299 plus Bifidobacterium Cure21) in patients with poor ileal pouch function: a randomised controlled trial. Scand J Gastroenterol 2016;
  12. Canaviri-Paz P, Oscarsson E, Kjellström A, Olsson H, Jois C, Håkansson Å. Effects on Microbiota Composition after Consumption of Quinoa Beverage Fermented by a Novel Xylose-Metabolizing L. plantarum Strain. Nutrients 2021;13(10):3318. PubMed

See these in context on the Lactiplantibacillus Plantarum monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring